Company: HSDTW
Filing Date: 2025-05-02
Form Type: DEF 14A
Source: 0001104659-25-044128
Chunk: 48

Company: Solana Co
Filing Date: 2025-05-02
Form: DEF 14A
Chunk 48
---
., a Delaware corporation (the “

#### Company
”) sponsors the Helius Medical Technologies, Inc. 2022 Equity Incentive Plan, as amended (the “

#### Plan
”).

B. The Plan is amended by this Amendment 2 (this “

#### Second Amendment
”) in the following respects, effective from and after the date this Second Amendment is approved by the stockholders of Helius Medical Technologies, Inc., in accordance with Section 7(b) of the Plan. Following such effective date, any reference to the “Plan” shall mean the Plan, as amended by this Second Amendment. All capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Plan.

### AMENDMENT
1.

Section 2 of the Plan is hereby amended by adding the following at the end of subsection 2(a) of the Plan:

“In addition, on the 10th calendar day following the first closing of a registered offering of the Company’s Common Stock that occurs after on or after May 15, 2025, the aggregate number of shares of Common Stock that may be issued pursuant to Awards will automatically increase to an amount equal to 20% of the Fully Diluted Shares as of the such date; provided, however that the Board may act prior to the effective date of any such increase to provide that the increase will be a lesser number of shares of Common Stock.”

2.

Section 14(cc) is hereby amended and restated as follows:

“

#### Fully Diluted Shares
” shall mean an amount equal to the number of shares of Common Stock (i) outstanding and (ii) issuable upon exercise, conversion or settlement of outstanding Awards under the Plan and any other outstanding options, warrants or other securities of the Company that are (directly or indirectly) convertible or exchangeable into or exercisable for shares of Common Stock, and in the case of warrants, assuming the exercise of any zero cash exercise provision, in each case as of the close of business of the Company on such date and without regard to any vesting conditions or other limitations on the immediate ability to convert, exchange or exercise such rights. For purposes of calculating the number of Fully Diluted Shares, if the number of shares subject to an outstanding right to acquire shares is variable, then the number of shares of Common Stock issuable upon exercise, conversion, exchange or settlement of the right shall be the maximum number of shares that could be received under such right.”

3.

Except as set forth in this